Sign in
TerminatedNo phase

Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals

Key facts

Who runs it
Swiss Paraplegic Research, Nottwil
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
50 people enrolled
Started
13 Aug 2018
Ended
31 Dec 2024
Type of study
Observational
Treatments tested
  • measurement of tumor mRNA concentration in urine
Record updated
13 February 2025
Why it stopped
insufficient recruitment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Symptoms suspicious of bladder cancer (haematuria, ultrasonic and cystoscopy findings)
  • Chronic spinal cord injury for a minimum of 3 years
  • Informed Consent as documented by signature

Who cannot take part

  • Previous intravesical treatment (e.g. bladder irrigation, botulinum toxin injection) < 2 weeks)
  • History of bleeding disorder
  • Acute, symptomatic urinary tract infection
  • Age < 18 years
  • Bladder augmentation
  • Pregnancy
  • Urolithiasis

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Bladder cancer is a well-recognized complication in spinal cord injury (SCI) individuals. The observed incidence rates in SCI individuals are considerably higher compared to the general population. Bladder cancer in SCI individuals tends to present at an earlier age compared to the general population. Furthermore, bladder cancer in SCI individuals is more commonly invasive and at a more advanced stage at the time of diagnosis compared to bladder cancer in the general population. Individuals with bladder cancer commonly present with hematuria and other urinary symptoms. The gold standard for diagnosis is cystoscopy. However in SCI individuals, hematuria may get attributed to catheter irritation or trauma or an urinary tract infection. Furthermore, the bladder wall commonly presents with various changes under cystoscopic examination masking the presence of a bladder wall mass. Thus, diagnosis of bladder cancer in SCI individuals can be complicate.

Read full original descriptionShow less

There is a novel test available (GeneXpert® Bladder Cancer Detection, Cepheid International, Sunnyvale, CA, USA) for the measurement of mRNA bladder tumor markers in the urine. The diagnostic accuracy of this test has been investigated in non-SCI individuals with symptoms suspicious for bladder cancer. The test showed high sensitivity and specificity values and is thus a promising diagnostic or screening tool.. However, the diagnostic accuracy of the test has not yet been investigated in SCI individuals.

The primary objective of the proposed study is to investigate whether urine mRNA tumor marker levels in spinal cord injury individuals with symptoms and findings suspicious for bladder cancer are a discriminator between individuals suffering from bladder cancer and those not suffering from cancer.

Individuals presenting with symptoms suspicious of bladder cancer will undergo ultrasonic and cystoscopic examination of the bladder. An urine sample will be taken, and the bladder will be flushed for collecting a bladder fluid sample. In patients with bladder wall findings suspicious of cancer, a bladder wall biopsy will be taken, according to clinical standard practice. The bladder fluid and the bladder wall biopsy will be submitted for cytology and histopathology examination, respectively. Tumor mRNA levels will be measured in the urine sample.

Treatments tested

  • measurement of tumor mRNA concentration in urine

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Quantitative Evaluation of a Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Individuals With Symptoms or Clinical Findings Suspicious for Bladder Cancer
Record updated
13 February 2025